2005, Number 1
Comparison of autologous serum, olopatadine hydrochloride and ketotifen fumarate in the treatment of allergic conjunctivitis.
PDF size: 125.33 Kb.
ABSTRACTPurpose: To describe the effectiveness of the autologous serum in the treatment of allergic conjunctivitis compared with previous treatments.
Methods: A prospective, comparative, longitudinal and controlled blind study was carried out. Inclusion criteria: 3 years of age or more, chronic or acute symptoms, no previous treatment (3 months). Non-inclusion criteria: other ocular diseases, HIV+ or hepatitis B-C +.
Autologous serum (20%) was prepared. One month treatment with solution «A» (autologous serum) 1drop every 2 hours, was given in one eye, and solution «B» (Olopatadine) or solution «C» (Ketotifen) 1 drop bid, in the other eye. Signs and symptoms were scored after 2 weeks and 1 month.
Results: 20 eyes of 10 patients were studied, mean age 12.4 years. Mean overall symptoms score: 5.25 points before treatment with improvement to a score of 0.7 points; and mean overall signs score: 5 points with improvement to a score of 3.7 points, both after one month treatment. No adverse reactions.
Conclusions: Autologous serum has a very similar effect in resolving symptoms as previous established treatments. Two IgE an IgG dependent theories could be described, thus further investigations are needed to determine the exact mechanism of action, and serum concentrations.
Nussenblatt R, Whitcup S, Palestine A. Uveitis. Fundamentals and Clinical Practice. 2a Ed. Ed. Mosby, 1996.
2. Aguilar A. Estudio Comparativo de la Eficiencia Clínica y la Tolerancia en el Manejo de Conjuntivitis Alérgica Estacional con Clorhidrato de Olopatadina 0.1% versus Fumarato de Ketotifeno 0.05%. Acta Ophthalmol Scand 2000; 78: 52-55.
3. Santos C, Huang A, Abelson M y cols. Efficacy of Lodoxamide 0.1% Ophthalmic Solution in Resolving Corneal Epitheliopathy Associated with Vernal Keratoconjunctivitis. Am J Ophthalmol 1994; 117: 488-497.
4. Goto E, Shimmura S, Shimazaki J, Tsubota K. Treatment of superior limbic keratoconjunctivitis by application of autologous serum. Cornea 2001; 20(8): 807-810.
5. Tsubota K, Goto E, Shimmura S, Shimazaki J. Treatment of persistent corneal epithelial defect by autologous serum application. Ophthalmology 1999; 106(10):1984-1989.
6. Tsubota K, Goto E, Fujita H, Ono M, Inoue H, Saito I, Shimmura S. Treatment of dry eye by autologous serum application in Sjogren’s syndrome. Br J Ophthalmol 1999; 83(4): 390-395.
7. Poon AC, Geerling G, Dart JK, Fraenkel GE, Daniels JT. Autologous serum eyedrops for dry eyes and epithelial defects: clinical and in vitro toxicity studies. Br J Ophthalmol 2001; 85(10): 1188-1197.
8. Tananuvat N, Daniell M, Sullivan LJ, Yi Q, McKelvie P, McCarty DJ, Taylor HR. Controlled study of the use of autologous serum in dry eye patients. Cornea 2001; 20(8): 802-806.
9. Geerling G, Hartwig D. Autologous serum-eye-drops for ocular surface disorders. A literature review and recommendations for their application. Ophthalmology 2002; 99(12): 949-959.
10. Garcia Jimenez V, Veiga Villaverde B, Baamonde Arbaiza B, Cahue Carpintero I, Celemin Vinuela ML, Simo Martinez RM. The elaboration, use and evaluation of eye-drops with autologous serum in corneal lesions. Farm Hosp 2003; 27(1): 21-57.
11. Velasco P, Baca O, Velasco R, Viggiano D, Cardona C. Topic Cyclosporine “A” in the Management of Allergic Conjunc-tivitis. ARVO Meeting 2003.
12. Del Castillo JM, de la Casa JM, Sardina RC, Fernandez RM, Feijoo JG, Gomez AC, Rodero MM, Sanchez JG. Treatment of recurrent corneal erosions using autologous serum. Cornea 2002; 21(8): 781-783.